Opiant Pharmaceuticals (OPNT) Stock Price, News & Analysis

Company Overview

Opiant Pharmaceuticals, Inc. is a pharmaceutical company, which engages in the development of pharmaceutical solutions for common addictions and related disorders. The firm focuses on developing treatment to reverse opioid overdoses, treatment for overweight and obese patients with binge eating disorder and treatment for patients with Bulimia Nervosa. Its principal product Naloxone is a medicine which is available through injection can reverse the overdose of prescription and illicit opioids. The company was founded on June 21, 2005 and is headquartered in Santa Monica, CA.

Key Stats

• Today's Range: N/A
• 50-Day Range: $20.03 to $21.10
• 52-Week Range: N/A
• Volume: 562,700 shs
• Average Volume: 77,920 shs
• Market Capitalization: $108.83 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

OPNT Stock Analysis - Frequently Asked Questions

How were Opiant Pharmaceuticals' earnings last quarter?

Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) posted its earnings results on Thursday, November, 11th. The technology company reported $0.56 earnings per share for the quarter, beating analysts' consensus estimates of $0.15 by $0.41. The technology company earned $16.34 million during the quarter, compared to analyst estimates of $12.45 million. Opiant Pharmaceuticals had a negative net margin of 147.90% and a negative trailing twelve-month return on equity of 97.03%.

What other stocks do shareholders of Opiant Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Opiant Pharmaceuticals investors own include NIO (NIO), Advanced Micro Devices (AMD), NVIDIA (NVDA), Alibaba Group (BABA), Cara Therapeutics (CARA), Dynavax Technologies (DVAX) and AcelRx Pharmaceuticals (ACRX).

Company Calendar

• Last Earnings: 11/11/2021
• Today: 1/27/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:OPNT
• CUSIP: N/A
• CIK: 1108924
• Web: www.opiant.com
• Phone: (310) 598-5410
• Fax: 917-322-2105
• Employees: 37
• Year Founded: 2009

Profitability

• EPS (Most Recent Fiscal Year): ($6.56)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $3.01 million
• Net Margins: -147.90%
• Pretax Margin: -147.84%
• Return on Equity: -97.03%
• Return on Assets: -59.66%

Debt

• Debt-to-Equity Ratio: 0.60
• Current Ratio: 5.48
• Quick Ratio: 5.48

Sales & Book Value

• Annual Sales: $47.78 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: 24.75
• Book Value: $9.92 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 5,270,000
• Free Float: 3,865,000
• Market Cap: $108.83 million
• Optionable: Not Optionable
• Beta: 0.84